Latest Indonesia News

BPH Global Ltd has reported a promising start to its seaweed sales business in Indonesia, generating A$150,646 in revenue during its first month of operations. Early sales to South Korean and Indonesian buyers highlight growing demand and sustainability commitments.

Bass Oil Limited reported steady oil production in May with a 3% increase in output and announced plans to acquire the Vanessa gas field, marking a strategic pivot towards gas production in Australia’s evolving energy landscape.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

VBX Limited is set to raise $10 million through an initial public offering to fund the development of its Wuudagu Bauxite Project in Western Australia, supported by a positive pre-feasibility study and strong market fundamentals driven by China’s growing aluminium demand.

BPH Global Ltd has completed its second seaweed sale under a strategic partnership in Indonesia, marking steady progress in its supply network expansion and operational execution.

Cokal Limited has secured US$15 million in strategic debt funding to ramp up metallurgical coal production at its BBM mine, while terminating all agreements with Cratus due to non-performance.

Austin Engineering has raised its FY25 revenue guidance to $370 million, driven by strong growth in the Americas, but has lowered its EBIT forecast due to operational challenges in Chile.

Far East Gold has commenced a 36-hole diamond drilling program at its Idenburg Gold Project in Papua, aiming to expand its current 540,000oz inferred resource and validate a multi-million-ounce exploration target.

Ovanti Limited is set to raise approximately $1 million through a two-tranche share placement to support its US buy now, pay later expansion and ongoing legal matters.

Recce Pharmaceuticals has completed a A$15.8 million capital raise to fund pivotal Phase 3 clinical trials and progress its FDA application, positioning the company for potential commercial breakthroughs in antibiotic-resistant infections.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Ordinary Shares Group Limited has announced a combined share purchase plan and placement to raise approximately NZD 1.78 million, aiming to accelerate its international expansion and cervical cancer screening initiatives.